MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Open

BrancheGesundheitswesen

102.69 -4.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

100.88

Max

107.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

530M

1.8B

Verkäufe

29M

7.6B

KGV

Branchendurchschnitt

274.553

57.333

EPS

1.9

Dividendenrendite

3.02

Gewinnspanne

23.557

Angestellte

17,600

EBITDA

-655M

3.1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+9.79% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.02%

2.63%

Nächste Dividendenausschüttung

26. Juni 2025

Nächstes Ex-Dividendendatum

13. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

8.7B

130B

Vorheriger Eröffnungskurs

107.09

Vorheriger Schlusskurs

102.69

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Gilead Sciences Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 20:17 UTC

Ergebnisse

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11. Feb. 2025, 21:17 UTC

Ergebnisse

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24. Apr. 2025, 20:08 UTC

Ergebnisse

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Rev $6.67B >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q EPS $1.04 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q EPS $1.04 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Net $1.32B >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24. Apr. 2025, 20:02 UTC

Ergebnisse

Gilead Sciences 1Q Rev $6.7B >GILD

11. Apr. 2025, 09:30 UTC

Top News

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19. März 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11. Feb. 2025, 22:13 UTC

Market Talk
Ergebnisse

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11. Feb. 2025, 21:06 UTC

Ergebnisse

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Raises Dividend 2.6%>GILD

11. Feb. 2025, 21:02 UTC

Ergebnisse

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Peer-Vergleich

Kursveränderung

Gilead Sciences Inc. Prognose

Kursziel

By TipRanks

9.79% Vorteil

12-Monats-Prognose

Durchschnitt 116.79 USD  9.79%

Hoch 140 USD

Tief 89 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gilead Sciences Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

24 ratings

18

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

105 / 106.5Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.